We could not find any results for:
Make sure your spelling is correct or try broadening your search.
[Ad hoc-Mitteilung gemäss Art. 53 KR] Verkäufe der Roche-Gruppe steigen im ersten Quartal um 2% (CER); beide Divisionen Pharma und Diagnostics wachsen im hohen einstelligen Bereich ohne...
[Ad hoc announcement pursuant to Art. 53 LR] Roche sales increase by 2% (CER) in first quarter with both divisions growing in high single digit ex COVID-19 Group sales grew by 2%1 at constant...
FDA approves Roche’s Alecensa as the first adjuvant treatment for people with ALK-positive early-stage lung cancer Approval based on Phase III ALINA study showing Alecensa reduced the risk of...
Roche’s subcutaneous OCREVUS one-year data demonstrates near-complete suppression of clinical relapses and brain lesions in patients with progressive and relapsing forms of MS Results from the...
[Ad hoc announcement pursuant to Art. 53 LR] Roche’s Columvi meets primary endpoint of overall survival in people with relapsed or refractory diffuse large B-cell lymphoma in Phase III STARGLO...
Roche granted FDA Breakthrough Device Designation for blood test to support earlier Alzheimer's disease diagnosis The Elecsys® pTau217 plasma biomarker test is being developed as part of an...
Roche receives FDA approval for the first molecular test to screen for malaria in blood donors The cobas Malaria test is the first FDA-approved molecular test to screen U.S. blood donors for...
Roche Generalversammlung 2024 Alle Anträge des Verwaltungsrates genehmigtSeverin Schwan erneut als Präsident des Verwaltungsrates gewählt; alle weiteren zur Wahl stehenden Verwaltungsrätinnen und...
Assemblée générale 2024 de Roche Adoption de toutes les propositions du Conseil d’administrationRéélection de Severin Schwan à la présidence du Conseil d’administration ; confirmation de tous les...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 229.2 | 229.2 | 229.2 | 2450 | 229.2 | DE |
4 | 0 | 0 | 229.2 | 229.2 | 229.2 | 1865 | 229.2 | DE |
12 | 0 | 0 | 229.2 | 229.2 | 229.2 | 7125 | 229.2 | DE |
26 | 0 | 0 | 229.2 | 229.2 | 229.2 | 6414 | 229.2 | DE |
52 | 0 | 0 | 229.2 | 229.2 | 229.2 | 6793 | 229.2 | DE |
156 | 0 | 0 | 229.2 | 229.2 | 229.2 | 6134 | 229.2 | DE |
260 | 0 | 0 | 229.2 | 229.2 | 229.2 | 4520 | 229.2 | DE |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions